Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CCKAR | P32238 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506558 | 0.90 | MEN1 (0.41) | HTTMAPTTSHRUSP2MEN1 | |
| SCHEMBL2999008 | 0.88 | PDPK1 (0.42) | CCKBR | |
| SCHEMBL14506561 | 0.84 | HTT (0.51) | HTTMAPTTSHRUSP2MEN1 | |
| SCHEMBL281876 | 0.79 | FABP4 (0.37) | — | |
| SCHEMBL3008462 | 0.77 | MEN1 (0.36) | HTTTSHRMEN1KMT2ACCKBR | |
| SCHEMBL27791534 | 0.76 | ALDH1A1 (0.44) | HTTMAPTTSHRUSP2MEN1 | |
| SCHEMBL14506551 | 0.75 | HTT (0.38) | HTTMAPTTSHRUSP2MEN1 | |
| SCHEMBL281966 | 0.75 | ALDH1A1 (0.42) | HTTMAPTTSHRUSP2MEN1 | |
| SCHEMBL3330877 | 0.74 | FABP4 (0.36) | — | |
| SCHEMBL14506502 | 0.74 | SCN9A (0.51) | HTTMAPTTSHRUSP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103271906-A | Use of spiro-oxindole compounds as therapeutic agents | XENON PHARMACEUTICALS INC | 2013-09-04 | — | — | CN | disclosed |
| CN-101631546-A | Use of spiro-indolone compounds as therapeutic agents | XENON PHARMACEUTICALS INC | 2010-01-20 | — | — | CN | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | HTT 354/4885MAPT 1540/4885TSHR 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.